Research programme: oligonucleotide therapeutics for muscular dystrophy - OliPass
Latest Information Update: 12 Jul 2016
At a glance
- Originator OliPass
- Class Oligonucleotides
- Mechanism of Action Dystrophin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Muscular dystrophies
Most Recent Events
- 12 Jul 2016 Early research in Muscular dystrophies in South Korea (unspecified route)